The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States. Metabolic syndrome (MS) components are highly prevalent in NAFLD. Our aim is to assess the relationship of NAFLD and MS with long-term outcome of mortality.The Third National Health and Nutrition Examination Survey (NHANES) was utilized. NAFLD was diagnosed by ultrasound in the presence of hepatic steatosis and no other causes of chronic liver disease. History of MS and its components were obtained from self-reported NHANES questionnaires. Mortality was obtained from Mortality-Linkage File, through December 31, 2011. Chi-square test was used for categorical variables and Cox proportional models estimated hazard ratios with 95% confidence interval.NAFLD cohort (n = 3613) had a median age of 43 years, 73% white, and 50% male. NAFLD group with at least one MS condition was significantly older, had higher body mass index, more likely to have insulin resistance, and heart disease compared to NAFLD group without MS. Over 19-years of follow-up, 1039 people died. Compared to NAFLD patients without MS, presence of one MS component increased the risk of mortality at 8-year (2.6% vs 4.7%) and 16-year (6% vs 11.9%) (P < .001). After adjusting for socio-demographic factors, NAFLD with all MS components was associated with overall, cardiac and liver-mortality. Increased number of MS components was associated with lower survival (P < .0001).Patients with NAFLD and MS have higher mortality risk compared to NAFLD patients without MS. These NAFLD patients should be prioritized for the development of treatment regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, having several cardiometabolic risk factors confers a greater risk of progressive liver damage and major adverse liver outcomes. 17,35”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationEckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
Self-citationEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D. B., Blissett, R., Henry, L. L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,308
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki‐Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,296
Kotronen, A., & Yki‐Järvinen, H. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 793
The Natural Course of Non-Alcoholic Fatty Liver Disease
Bertot, L. C., & Adams, L. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 638
Cited by
Sorted by citations
Items 101–200 of 221
Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016
Paik, J. M., Henry, L. L., Golabi, P., Alqahtani, S. A., Trimble, G., & Younossi, Z. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz509 · Cited by 19
Self-citationMetabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease
Elsaid, M. I., Bridges, J. F. P., Li, N., & Rustgi, V. K. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.02.002 · Cited by 19
Henney, A. E., Riley, D. R. J., Hydes, T., Anson, M., Ibarburu, G. H., Zhao, S. S., Cuthbertson, D. J., & Alam, U. (2024) · Liver International · doi:10.1111/liv.16086 · Cited by 20
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
Self-citationLuthra, R., & Sheth, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03085-4 · Cited by 21
Niriella, M. A., Kasturiratne, A., Beddage, T., Withanage, S. A., Goonatilleke, D. C., Abeysinghe, C. P., Mel, R. T. D., Balapitiya, T. L., Silva, S. D., Dassanayake, A. S., et al. (2019) · Liver International · doi:10.1111/liv.14237 · Cited by 17
Is liver steatosis a disease or the emperor’s new clothes?
Krag, A. A., Tacke, F., Israelsen, M. E., & Younossi, Z. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2025.12.026 · Cited by 16
Self-citationWang, M., Zhao, Y., He, Y., Zhang, L., Liu, J., Zheng, S., & Bai, Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.018 · Cited by 17
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Obesity · doi:10.1002/oby.23250 · Cited by 18
Self-citationWong, V. W., Neff, G. W., Bisceglie, A. M. D., Bai, R., Cheng, J., Meng, Y., Liberman, A., Liu, L., & Gunn, N. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0145 · Cited by 15
Colca, J. R. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1715940 · Cited by 17
“Big Data” Approaches for Prevention of the Metabolic Syndrome
Jiang, X., Zhang, Y., Wang, S., & Deng, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.810152 · Cited by 17
Patel‐Sanchez, N., Perito, E. R., Tsai, P., Raymond‐Flesch, M., Lodish, M. B., & Sarkar, M. A. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0527 · Cited by 15
Türkmen, K., Özer, H., & Kusztal, M. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051308 · Cited by 17
Nonalcoholic Fatty Liver Disease
Yip, T. C., Wong, G. L., Wong, V. W., Goh, G. B., & Chan, W. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.12.003 · Cited by 15
Non-alcoholic fatty liver disease: digest 2021
Сергеевна, К. Т., & Livzan, V. A. (2021) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro20211002127 · Cited by 13
Ala, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15
Saenz, E., Montagut, N. E., Wang, B., Stein-Thöringer, C. K., Wang, K., Weng, H., Ebert, M. P., Schneider, K. M., Li, L., & Teufel, A. (2024) · Engineering · doi:10.1016/j.eng.2024.03.019 · Cited by 13
Medina, S. P., Kim, R. G., Magee, C., Stapper, N., & Khalili, M. (2023) · Obesity Science & Practice · doi:10.1002/osp4.688 · Cited by 12
Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea
Park, H., Yoon, E. L., Kim, M., Cho, S., Kim, J. H., Jun, D. W., & Nah, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061474 · Cited by 11
Doustmohammadian, A., Saeidlou, S. N., Esfandyari, S., Gholizadeh, E., Maadi, M., Motamed, N., Ajdarkosh, H., Khoonsari, M., Clark, C. C. T., & Zamani, F. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.921415 · Cited by 11
Solomon, A., Cipăian, C. R., Negrea, M. O., Boicean, A., Mihăilă, R. G., Beca, C., Popa, M. L., Grama, S. M., Teodoru, M., & Neamtu, B. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175657 · Cited by 11
Kim, J. Y., Lee, T., & Chung, T. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.01.023 · Cited by 10
Nishihara, T., Miyoshi, T., Nakashima, M., Takashi, M. I. K. I., Toda, H., Yoshida, M., Ichikawa, K., Osawa, K., & Yuasa, S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02268-1 · Cited by 10
Younossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castéra, L., Betel, M., Henry, L. L., & Zelber‐Sagi, S. (2025) · Liver International · doi:10.1111/liv.70311 · Cited by 12
Self-citationRan, Q., Gan, Q., Zhu, Y., Li, S., Shen, L., Duan, X., Zhu, X., & Huang, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116322 · Cited by 10
Predicting Liver-Related Outcomes in Steatotic Liver Disease
Younossi, Z. M. (2024) · JAMA · doi:10.1001/jama.2024.0799 · Cited by 9
Self-citationLe, P., Tatar, M., Rothberg, M. B., Wilson, L., Allende, D. S., Diehl, A. M., Loomba, R. S., Chalasani, N., Neuschwander‐Tetri, B. A., Kowdley, K. V., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003455 · Cited by 8
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Terracciani, F., Falcomatà, A., Gallo, P., Picardi, A., & Gentilucci, U. V. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00934-0 · Cited by 9
El-Wahab, E. W. A., El-Abedin, R. A. Z., Ahmed, W. M., & Shatat, H. Z. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.06.020 · Cited by 8
Eisenberg, D., Arnow, K. D., Barreto, N. B., Davis‐Lopez, K. M., LaVela, S. L., Frayne, S. M., Nevedal, A., Wu, J. C., & Harris, A. H. S. (2022) · Obesity Science & Practice · doi:10.1002/osp4.643 · Cited by 6
Wang, L., Liu, K., Deng, L., Zhou, G., Qian, W., & Xu, K. (2023) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-023-04694-5 · Cited by 6
Do, A., Ilagan‐Ying, Y. C., Mehal, W. Z., & Lim, J. K. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1811674 · Cited by 7
Keskin, E. B., & Çoban, G. (2019) · Medeniyet Medical Journal · doi:10.5222/mmj.2019.48640 · Cited by 6
Non-alcoholic Fatty Liver Disease: A Global Public Health Issue
Kaya, E., & Yilmaz, Y. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_24 · Cited by 6
Barati, M., Teimouri, A., Feizi, A., Iraj, B., & Karimifar, M. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_830_23 · Cited by 5
Couret, A., King, J. A., Pereira, B., Courteix, D., Obert, P., Vinet, A., Walther, G., Lesourd, B., Chapier, R., Žák, M., et al. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102461 · Cited by 5
Pérez-Díaz-del-Campo, N., Castelnuovo, G., Ferro, A., Caviglia, G. P., Rosso, C., Dileo, E., Guariglia, M., Armandi, A., Saba, F., Saracco, G. M., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003594 · Cited by 5
Self-citationWaddell, T., Namburete, A. I. L., Duckworth, P., Fichera, A., Telford, A., Thomaides-Brears, H. B., Cuthbertson, D. J., & Brady, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1063882 · Cited by 5
Abdulfattah, A. A., Elmakki, E. E., Maashi, B. I., Alfaifi, B. A. H., Almalki, A. S., Alhadi, N. A. A., Majrabi, H., Kulaybi, A., Salami, A., & Hakami, F. I. (2024) · Cureus · doi:10.7759/cureus.53111 · Cited by 5
Neuschwander‐Tetri, B. A., Morris, H., Mospan, A. R., Yu, F., Muñoz, B., Abraham, S., Fried, M. W., Barritt, A. S., Al‐Sayyed, L., Sanyal, A. J., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70278 · Cited by 5
Sogabe, M., Okahisa, T., Kurihara, T., Kagawa, M., Kagemoto, K., Kida, Y., Tomonari, T., Taniguchi, T., Okamoto, K., Miyamoto, H., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s298326 · Cited by 5
Laursen, T. L., Kjær, M. B., Kristensen, L., & Grønbæk, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092271 · Cited by 5
Liver–Spleen Ratio: Can It Be Used for the Prediction of Coronary Artery Disease?
Poyraz, N., Özer, H., Baloğlu, İ., Kadıyoran, C., Yılmaz, P. D., Sertdemir, A. L., & Türkmen, K. (2022) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2022.1787 · Cited by 5
Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time?
Younossi, Z. M., & Henry, L. L. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.11.024 · Cited by 5
Self-citationMASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 6
Jacobson, I. M., Wong, V. W., Castéra, L., Anstee, Q. M., Noureddin, M., Cusi, K. J., Harrison, S. A., Bugianesi, E., & Younossi, Z. M. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001780 · Cited by 4
Self-citationAkbariRad, M., Rad, M. P., Nobakht, H., Ghalibaf, A. M., Firoozi, A., Torshizian, A., Bina, A. R., Namdar, A. B., & Sadeghi, M. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03302-y · Cited by 4
Botacin, E. C., Duarte, S. M. B., Stefano, J. T., Barbosa, M. E. D., Pessoa, M. G., & de Oliveira, C. P. M. S. (2024) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612023-128 · Cited by 4
Ramírez, A., Donjuán-Loredo, G., Espinosa‐Tanguma, R., Salgado‐Delgado, R., Rodríguez‐Aranda, M. C., Guevara, E., & Ramírez‐Elías, M. G. (2025) · The Analyst · doi:10.1039/d5an00533g · Cited by 4
Younes, R., & Bugianesi, E. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0422-x · Cited by 4
Polyunsaturated fatty acids: omega-3 and omega-6 and nonalcoholic fatty liver disease
Berezhnaya, I. V., Zakharova, I. N., Simakova, M. A., & Sgibneva, A. I. (2021) · Pediatrics Consilium Medicum · doi:10.26442/26586630.2021.4.201348 · Cited by 4
Alam, S., & Fahim, S. M. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i10.1203 · Cited by 4
The crystallisation of Poly (aryl ether etherketone) (PEEK) and its carbon fibre composites
Herrod-Taylor, A. J. (2011) · UPT. Syiah Kuala University Library (Syiah Kuala University) · Cited by 4
Rey-Garcia, B., Chacon, M. T. R., Rosas‐Blum, E. D., & Leiner, M. A. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102197 · Cited by 3
Lu, Y., Xia, Q., Wu, L., & Xie, Z. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1026054 · Cited by 3
Tse, C., Lisanti, N., Iderstine, M. G. V., Uhanova, J., Minuk, G. Y., & Faisal, N. (2023) · Canadian Liver Journal · doi:10.3138/canlivj-2023-0006 · Cited by 3
Association between SPISE and NAFLD in patients with type 2 diabetes
Zhao, H., Ji, B., Wang, X., Shi, S., Sheng, J., Ma, X., Ban, B., & Gao, G. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1454938 · Cited by 3
Singh, V., Chattopadhyay, P., Fatima, F., Singh, P., Pandey, R., Agrawal, A., & Roy, S. S. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167886 · Cited by 3
Clinical features of the comorbid course of non-alcoholic fatty liver disease and gallstone disease
Александровна, Ч. Н., Livzan, M. A., & Сергеевна, К. Т. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.08.000764 · Cited by 3
Lara, I. P., Ortiz‐López, M. G., Bonilla‐Delgado, J., Pérez-Escobar, J., Godínez-Aguilar, R., Luévano‐Contreras, C., Espinosa-García, A. M., Duran, J. P., Alonso-Themann, P. G., Nolasco‐Quiroga, M., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101562 · Cited by 5
MAFLD AND NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality?
Lombardi, R., Cespiati, A., Francione, P., Cinque, F., Fargion, S. R., & Fracanzani, A. L. (2021) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.13 · Cited by 3
Association between obesity profile and non-alcoholic fatty liver by race/ethnicity
Martin, G., Schrode, K., & Shaheen, M. A. (2021) · Annals of Clinical Endocrinology and Metabolism · doi:10.29328/journal.acem.1001017 · Cited by 3
Developing a Novel Continuous Metabolic Syndrome Score: A Data Mining Based Model
Saffarian, M., Babaiyan, V., Namakin, K., Taheri, F., & Kazemi, T. (2021) · Journal of artificial intelligence and data mining · doi:10.22044/jadm.2021.10433.2179 · Cited by 3
Swaroop, S., Biswas, S., Mehta, S., Aggarwal, A., Arora, U., Agarwal, S., Chavan, A., Nayak, B., & Shalimar, S. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.102559 · Cited by 3
Pustjens, J., van Kleef, L. A., Younossi, Z. M., Moreno, C., Janssen, H. L. A., Thiele, M. S., & Brouwer, W. P. (2025) · Hepatology Research · doi:10.1111/hepr.70067 · Cited by 2
Self-citationZhang, P., Yang, S., Hu, R., Peng, T., Yu, P., Zeng, Y., Ye, C., Wang, P., Dong, X., & Che, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335230 · Cited by 2
Sevostyanova, E. V., Nikolaev, Y. A., Polyakov, V. Y., & Митрофанов, И. М. (2019) · Current Hypertension Reviews · doi:10.2174/1573402115666190801104227 · Cited by 2
Nichtalkoholische Fettlebererkrankung
Roeb, E. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01448-z · Cited by 2
Esparham, A., Shoar, S., Mehri, A., Khorgami, Z., & Modukuru, V. R. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07238-w · Cited by 2
Henry, L. L., Paik, J. M., & Younossi, Z. M. (2022) · Hepatology · doi:10.1002/hep.32565 · Cited by 2
Self-citationUllah, S., Ali, A., Hanif, M. A., Kumar, A., Din, H. U., & Anis, R. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22164557 · Cited by 2
Xu, J., Piao, C., Qu, Y., Liu, T., Peng, Y., Li, Q., Zhao, X., Li, P., Wu, X., Fan, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924021 · Cited by 2
Alencar, R. S. D. S. M., Oliveira, C., Chagas, A., da Fonseca, L. D., Maccali, C., Saud, L. R. D. C., Xerfan, M., Stefano, J., Herman, P., D'Albuquerque, L. A., et al. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100097 · Cited by 3
BARRETO, B. F. D. M., Punaro, G., ELIAS, M. C., & Parise, E. R. (2022) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202203000-72 · Cited by 2
Kim, J., & Sohn, A. (2023) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2023.0036 · Cited by 1
Divya, K. P., Hari, P., Kanwar, N., Aggarwal, N., Dhoat, P. S., Liu, L., Kanwal, A., & Singh, S. P. (2023) · Advanced Gut & Microbiome Research · doi:10.1155/2023/5431615 · Cited by 1
The Effects of Traditional Asian Diet on Metabolism, Gut Microbiota, and Liver Tissue in NASH Rats
Mustika, S., Sofia, E. R. A., Sari, N. A. K., Poetri, L. N., Yudhanto, H. S., & Handayani, D. (2024) · Natural and Engineering Sciences · doi:10.28978/nesciences.1574444 · Cited by 1
Goon, M. D. M. E., Rahim, S. A., Kadir, S. H. S. A., Ibrahim, E., Mazlan, M., & Latip, N. A. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00412-4 · Cited by 1
Kalafateli, M., Aydin, B. S., Polat, B., Yee, M. S., Forlano, R., Izzi‐Engbeaya, C. N., Thursz, M. R., Mullish, B. H., & Manousou, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102705 · Cited by 1
Steatotic liver disease in patients with chronic hepatitis C
Janczura, J., Brzdęk, M., Flisiak, R., Dobrowolska, K., Brzdęk, K., Rzymski, P., & Zarębska‐Michaluk, D. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.113639 · Cited by 1
Sun, X., Wang, X., Younas, A., Wang, S., Sohail, M., Lv, J., Huang, Z., & Liu, Y. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04692-x · Cited by 1
Widmann, F. P., Häseli, S. P., Schattenfroh, J., Bieling, J., Jaitner, N., Muche, M., Puengel, T., Tacke, F., Asbach, P., Geisel, D., et al. (2026) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-2807-9946 · Cited by 2
Liou, W. L., Pei, Y., Teh, K. K., Cheah, M. C. C., Leow, W. Q., Lim, T. K., & Goh, G. B. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09870-1 · Cited by 1
Shi, T., Yue, H., Wang, W., Gao, Y., Xu, S., Gao, J., & Yin, C. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s603396 · Cited by 1
ENNEQUIN, G., BUCHARD, B., Pereira, B., BONJEAN, L., Courteix, D., Lesourd, B., CHAPIER, R., OBERT, P., VINET, A., WALTHER, G., et al. (2022) · Minerva Gastroenterology · doi:10.23736/s2724-5985.22.03139-4 · Cited by 1
How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting
Golabi, P., Shah, D., & Younossi, Z. M. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-1770984 · Cited by 1
Self-citationAkhtar, S., & Khan, A. U. (2020) · Advanced Journal of Graduate Research · doi:10.21467/ajgr.9.1.46-58 · Cited by 1
Effect of grapefruit juice on CYP2E1 gene expression in obese and control rats
Vahid, P. A., & Zia-Jahromi, N. (2021) · مجله علمی دانشگاه علوم پزشکی بیرجند · doi:10.32592/jbirjandunivmedsci.2021.28.3.104 · Cited by 1
Shin, J.-E., Choi, S. J., Lee, H. R., Han, K., Chang, J., Jeong, S., Choi, Y.-S., Lee, D., & Shin, D. W. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040546 · Cited by 1
Zheng, J., Wang, Z., & Feng, B. (2024) · medRxiv · doi:10.1101/2024.07.10.24310253 · Cited by 1
Bobeck, K. A., Ordway, S. M., Sadowski, B. W., Tritsch, A. M., & Singla, M. B. (2019) · OBM Hepatology and Gastroenterology · doi:10.21926/obm.hg.1902025
Бабак, О. Я., & Bashkirova, A. (2019) · Innovative Solutions in Modern Science · doi:10.26886/2414-634x.8(27)2018.4
Searching for biomarkers of non-alcoholic fatty liver disease and metabolic syndrome
delaCruz‐Villar, L. (2020) · Communities in ADDI (University of the Basque Country)
Mendonça, L. M., Mendonça, T. M., Noronha, V. F. C. M., Filho, R. C. S., Lima, S. O., & Cruz, J. F. (2021) · Arquivos Catarinenses de Medicina · doi:10.63845/a44a4820
Lim, Y. S. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/139651
MICROWAVE SPECTRUM AND STRUCTURE OF 2-CHLOROPROPIONITRILE
Ogata, T., & Yamashita, N. (1995) · The Knowledge Bank (The Ohio State University)
Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences
Younossi, Z. M., & Henry, L. L. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/22-00150 · Cited by 1
Self-citationZhao, X., Chen, S., Wang, X., Wang, Z., Sun, Y., Yang, C., Zheng, M., Wang, Y., Liao, W., Wu, S., et al. (2023) · medRxiv · doi:10.1101/2023.08.01.23293528
Metadata
- Authors
- Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M.
- Affiliations
- Inova Health System (US)
- Corresponding author
- Younossi, Zobair M.
- Venue
- Medicine
- Published
- 2018-03
- Volume
- 97
- Issue
- 13
- Pages
- e0214
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC5895395
- OpenAlex
- W2794816422
- Cited by
- 221
- References
- 46
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 32 · 2023: 25 · 2022: 33 · 2021: 36 · 2020: 24 · 2019: 24 · 2018: 9
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-sa
- Locations
- Medicine (publishedVersion, cc-by-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-sa)
- PubMed Central (publishedVersion, cc-by-sa)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, metabolic syndrome, mortality risk, hepatic steatosis, insulin resistance, cardiovascular mortality, liver-related mortality, body mass index, long-term survival
- MeSH terms
- Adult, Cardiovascular Diseases, Female, Humans, Insulin Resistance, Male, Middle Aged, Nutrition Surveys, Risk Factors, United States, Comorbidity, Body Mass Index, Proportional Hazards Models, Age Distribution, Sex Distribution, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review